Medicinal Usage of Cannabis and Cannabinoids

Victor R. Preedy BSc, PhD, DSc, FRSB, FRSPH, FRSC, FRCPath graduated with an Honours Degree in Biology and Physiology with Pharmacology. After gaining his University of London PhD, he received his Membership of the Royal College of Pathologists. He was later awarded his second doctorate (DSc), for his contribution to protein metabolism in health and disease. He is Professor of Clinical Biochemistry (Hon) at King’s College Hospital and Emeritus Professor of Nutritional Biochemistry at King’s College London. He has Honorary Professorships at the University of Hull, and the University of Suffolk. Professor Preedy was the Founding Director and then long-term Director of the Genomics Centre at King’s College London from 2006 to 2020. Professor Preedy has been awarded fellowships of the Royal Society of Biology, the Royal College of Pathologists, the Royal Society for the Promotion of Health, the Royal Institute of Public Health, the Royal Society for Public Health, the Royal Society of Chemistry and the Royal Society of Medicine. He carried out research when attached to the National Heart Hospital (part of Imperial College London), The School of Pharmacy (now part of University College London) and the MRC Centre at Northwick Park Hospital. He has collaborated with international research groups in Finland, Japan, Australia, USA, and Germany. To his credit, Professor Preedy has published over 750 articles, which includes peer-reviewed manuscripts based on original research, abstracts and symposium presentations, reviews and edited books. Dr. Patel is a Reader at the University of Westminster. After completing his PhD at King’s College London, he continued his research experience by undertaking his post-doctoral studies in the laboratory of Professor Cunningham in the Department of Biochemistry at the Wake Forest University School of Medicine, (Winston-Salem, NC, USA). This extensive project involved investigating mechanisms of hepatic mitochondrial ribosome dysfunction in alcoholic liver disease (ALD) using biophysical and proteomic techniques. These studies have led to new avenues in determining the pathology of ALD. His teaching areas at both post-graduate and undergraduate levels include clinical biochemistry, investigative pathology and laboratory investigation. Colin R. Martin RN, BSc, MSc, PhD, MBA, YCAP, FHEA, C.Psychol, AFBPsS, C.Sci is Professor of Clinical Psychobiology and Applied Psychoneuroimmunology and Clinical Director of the Institute of Health and Wellbeing at the University of Suffolk, UK. He is a Chartered Health Psychologist and a Chartered Scientist. He also trained in analytical biochemistry, this aspect reflecting the psychobiological focus of much of his research within mental health. He has published or has in press well over 300 research papers and book chapters. He is a keen book author and editor having written and/or edited more than 50 books. These outputs include the prophetic insight into the treatment of neurological disease, Handbook of Behavior, Food and Nutrition (2011), Nanomedicine and the Nervous System (2012), Oxidative Stress and Dietary Antioxidants in Neurological Disease (2020), Zika Virus Impact, Diagnosis, Control and Models (2021), Factors Affecting Neurodevelopment: Genetics, Neurology, Behavior and Diet (2021), Diagnosis and Treatment of Spinal Cord Injury (2022), The Neurobiology, Physiology, and Psychology of Pain (2022) and The Handbook of Lifespan Cognitive Behavioral Therapy: Childhood, Adolescence, Pregnancy, Adulthood, and Aging (2023). Professor Martin is particularly interested in all aspects of the relationship between underlying physiological substrates and behavior, particularly in how these relationships manifest in both acute and chronic psychiatric disorder. He has published original research germane to significant mental health disorders including the areas of schizophrenia, anxiety, depression, self-esteem, alcohol and drug dependency, high secure forensic mental health and personality disorder. He has a keen interest in the impact of postviral illness and is actively involved in clinical research post-Covid pandemic and in particular, the impact of Long Covid on psychological, neurological, physiological and social functioning. He is involved in collaborative International research with many European and Non-European countries.

• PrefaceI. Setting the scene and introductory chapters1. How medical cannabis may influence the future of medicineMartha Rosenthal2. Medical cannabis and cannabinoids: how best to extract components from plant material Roberta Costi3. Medicinal usage of cannabis and its impact on mental health among cancer patients and survivors Nicolas Hernandez Ortega, Ye Chen, Jessica Y. Islam, Diane Rodriguez, Marlene Camacho-Rivera and Denise Christina Vidot4. Cannabis sativa as a traditional phytomedicine: a new narrative covering different countries Md Nasir Ahmed, Tridib Paul, Md. Nur Kabidul Azam, Rownak Jahan and Mohammed Rahmatullah5. Medical use of cannabis in the middle east Bader Hamza Shirah, Mohammed Ahmed and Ruba Saleh6. What medicinal cannabis is used for: a focus on Canada Dean T. Eurich, Cerina Lee and Jason Dyck7. New York perspectives of medical cannabis laboratory analysisLingyun Li, Stacey Chmura, Christopher Judd and Bryan C. Duffy8. Potential roles of epigenetic memory on the quality of clonal cannabis plants: Content and profile of secondary metabolitesMohsen Hesami and Max Jones9. Aberrant use of medicinal cannabis: theoretical and empirical considerations Daniel Feingold10. Profile of older users of medical cannabis and cannabinoidsJoshua Brown11. Use of cannabidiol oil by caregivers: a focus on Alzheimer's diseaseMagdalena Leszko12. Medicinal use of cannabis: adverse events as a balanced perspectiveGiada Crescioli, Valentina Maggini, Fabio Firenzuoli, Alfredo Vannacci and Niccolo LombardiII. Physiological aspects and metabolic aspects13. Physiopathology and use of cannabinoids for fibrotic diseases Carmen del Rio and E. Munoz14. Cannabinoids in inflammation and atherosclerosis Leonor Thomson, Edward Moreira-Bahnson and Bruno Musetti15. Targeting the CB(2) receptors and other endocannabinoid elements to delay disease progression in cardiovascular diseasesShreesh Ojha16. BMI in cannabis users: regulation, mechanisms and public health impact Thomas ClarkIII. Neurological, psychological and behavioural aspects17. Neuroprotection by cannabis related products, cannabidiol and cannabigerol, and associated mechanisms of actionCarolina Echeverry Sr., Jimena Fagetti, Miguel Reyes-Parada and Cecilia Scorza18. Cannabis terpenes as neuroprotective agents: a focus on alpha-bisabololJohn Staton Laws, Srijan Shrestha and Scott D. Smid19. Cannabidiol in medicinal usage of stress: modelling investigations into cocaineM. Julia García-Fuster and Olga Valverde20. Medicinal cannabis and neurocognition impairmentCaroline MacCallum, April Christiansen, Lindsay Lo, Carly Pistawka, Michael Boivin and Melissa Snider-Adler21. Genetic models of audiogenic seizures: what they are and how cannabinoids and Cannabis-derived compounds can be used to alleviate their symptoms - an updated narrativeNorberto Garcia-Cairasco22. Addressing the validity of cannabinoid therapy as an option for the treatment of substance use disorderRose Chesworth, Erin McLemon and Tim KarlIV. Pharmacological and cellular aspects23. Cannabidiolic acid (CBDA), features and profiles: anti-hyperalgesic effects G. Singh, Katja Linher-Melville and Raphael Mechoulam24. Cannabis-drug interactions: implications for medicinal cannabis use Fran Gengo, Anna Mattle and Christopher Ralyea25. Cannabinoid receptor subtype 2 (CB2R): features and targets for medical applications Marialessandra Contino, Carmen Abate, Nicola Antonio Colabufo, Francesco Leonetti and Angela Stefanachi26. Medical use of cannabidiol and impact on cancer cell viability Kent E. Chair and Wesley Raup-Konsavage27. Anti-inflammatory and antioxidant and immunomodulatory effects of phytocannabinoid β‑caryophyllene: A mechanistic overviewVafa Baradaran Rahimi, Arghavan Memarzia and Prof. Vahid Reza AskariV. Symptom Control and Medicinal Uses28. Cancer patients and providers: Attitudes and beliefs of cannabis and cannabinoids use as a treatment Kimberson Tanco29. CBD (cannabidiol) use in breast cancer chemotherapyAna I. Torres-Suarez, Ana Isabel Fraguas-Sánchez and Ana Fernández-Carballido30. Sleep: cannabis and cannabinoids use Eric Murillo-Rodríguez31. Cannabis and cannabis related products and their uses in aiding sexual health of men and women　Lynnette Nathalie Lyzwinski32. Symptom control in palliative care settings: The role of cannabis-based medicines Maximillian Stevenson and Leah Sera33. Cannabidiol (CBD) Use in Fragile X Spectrum DisordersDevon Johnson and Randi J. Hagerman34. Hempseed (Cannabis sativa) and ameliorative effects in hypercholesterolemia NAVEEN KAUSHAL35. Benzodiazepines and cannabis useChad Alexander Purcell36. Features of (+)-trans-cannabidiol-2-hydroxy pentyland applications to disease: a focus on usage in diabetic nephropathy E. Munoz, Matthias Winkler, Marcus Goetz and Isabel Gonzalez Mariscal37. Medical use of cannabis: applications to Tourette syndromeKirsten R. Müller-Vahl and Natalia Szejko38. Cannabinoids and their use in chronic non-cancer pain: a new narrative review Stanley Sau-Ching Wong and Chi Wai Cheung39. Endometriosis: features and potential role of medical cannabisMike Armour and Justin Sinclair40. Cannabis usage for Crohn's disease and ulcerative colitis: a narrativeJoseph Feuerstein and Rajsavi Anand41. Medical cannabis and use in migraineJessica Jiang and Alasdair M. Barr42. Cannabidiol (CBD ) and potential in medicinal use in rheumatoid arthritis Torsten Lowin43. Role of Cannabinoids in Glaucoma: Lowering Intraocular Pressure or NeuroprotectionUjendra Kumar, Sneha Singh and Rishi Somvanshi44. Medicinal potential of anandamide as a representative endocannabinoid and its effect at the cellular level in skinAdrianna Maria Piasek and Anna SobiepanekVI. Resources45. Medical Cannabis and ResourcesRajkumar Rajendram